How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27,537 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Alternatives to systemic postnatal corticosteroids: Inhaled, nebulized and intratracheal. (PubMed)

Alternatives to systemic postnatal corticosteroids: Inhaled, nebulized and intratracheal. Concern about adverse outcomes with the use of systemic postnatal corticosteroids (PCS) for bronchopulmonary dysplasia (BPD) have led to the widespread use of alternative methods of administration in research and clinical care. Theoretically, administration of topical (directly to the lung) corticosteroids may allow for beneficial effects on the pulmonary system with a lower risk of undesirable side (...) effects compared with systemic administration. Current evidence suggests that inhaled corticosteroids may be an effective therapy in the management of developing BPD in preterm infants, but questions about their safety remain. An alternative to inhalation is the intratracheal administration of corticosteroids using surfactant as a vehicle, but this approach has only been studied in a limited number of infants. We review the evidence for the short-term clinical efficacy and safety of inhaled, nebulized

2019 Seminars in fetal & neonatal medicine

182. Topical tacrolimus for atopic dermatitis. (PubMed)

Topical tacrolimus for atopic dermatitis. Atopic dermatitis (AD) (or atopic eczema) is a chronic inflammatory skin condition that affects children and adults and has an important impact on quality of life. Topical corticosteroids (TCS) are the first-line therapy for this condition; however, they can be associated with significant adverse effects when used chronically. Tacrolimus ointment (in its 2 manufactured strengths of 0.1% and 0.03%) might be an alternative treatment. Tacrolimus, together (...) absorption. We evaluated clinical trials; case reports; and in vivo, in vitro, and animal studies; and didn't find any evidence that topical tacrolimus could cause skin atrophy.Tacrolimus 0.1% was better than low-potency corticosteroids, pimecrolimus 1%, and tacrolimus 0.03%. Results were equivocal when comparing both dose formulations to moderate-to-potent corticosteroids. Tacrolimus 0.03% was superior to mild corticosteroids and pimecrolimus. Both tacrolimus formulations seemed to be safe

Full Text available with Trip Pro

2015 Cochrane

183. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. (PubMed)

antihistamines) inhibit the action of histamine by blocking histamine H1 receptors, antagonising the vasoconstrictor, and to a lesser extent, the vasodilator effects of histamine. Mast cell stabilisers inhibit degranulation and consequently the release of histamine by interrupting the normal chain of intracellular signals. Topical treatments include eye drops with antihistamines, mast cell stabilisers, non-steroidal anti-inflammatory drugs, combinations of the previous treatments, and corticosteroids (...) Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Seasonal/perennial allergic conjunctivitis is the most common allergic conjunctivitis, usually with acute manifestations when a person is exposed to allergens and with typical signs and symptoms including itching, redness, and tearing. The clinical signs and symptoms of allergic conjunctivitis are mediated by the release of histamine by mast cells. Histamine antagonists (also called

Full Text available with Trip Pro

2015 Cochrane

184. Corticosteroid injections for tennis elbow

in well adults? What does the research evidence say? Step 1: The Cochrane Library The Cochrane Library has only a protocol for a review, but no systematic reviews exist. Step 2: TripDatabase & PubMed Next, I conducted a search using the TripDatabase PICO search tool (P: “tennis elbow”, I: “corticosteroid”, C: “placebo”, O: blank). This gave many results to evidence syntheses on the topic, but directly to the paper. I next did a search in PubMed: “lateral epicondylitis” and “corticosteroid (...) Corticosteroid injections for tennis elbow Corticosteroid injections for tennis elbow – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2015\/09\/mo_cover.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Sep 04 2015 Corticosteroid injections for tennis elbow By in , , , Journal reference: Olaussen

Full Text available with Trip Pro

2015 Morsels of Evidence

185. A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal (GNE-AD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2014 Clinical Trials

186. Fast itch relief in an experimental model for methylprednisolone aceponate topical corticosteroid activity, based on allergic contact eczema to nickel sulphate. (PubMed)

Fast itch relief in an experimental model for methylprednisolone aceponate topical corticosteroid activity, based on allergic contact eczema to nickel sulphate. Topical corticosteroids (TC) consistently show effectiveness against itch, a paradigmatic symptom, in various eczemas. Rapid itch relief is a therapeutic goal. The early response of itch to TC has not been adequately studied.To assess the effect on itch of a TC, methylprednisolone aceponate 0.1% ointment (MPA), in induced eczema

2014 Journal of the European Academy of Dermatology and Venereology

187. A comparative study of toluidine blue-mediated photodynamic therapy versus topical corticosteroids in the treatment of erosive-atrophic oral lichen planus: a randomized clinical controlled trial. (PubMed)

A comparative study of toluidine blue-mediated photodynamic therapy versus topical corticosteroids in the treatment of erosive-atrophic oral lichen planus: a randomized clinical controlled trial. Recently, photodynamic therapy (PDT) has been suggested as a new treatment option that is free from side effects for erosive-atrophic oral lichen planus (OLP). The purpose of this study was to compare the effect of toluidine blue-mediated photodynamic therapy (TB-PDT) with local corticosteroids (...) on treatment of erosive-atrophic OLP. In this randomized clinical trial, 25 patients with keratotic-atrophic-erosive oral lichen planus were allocated randomly into two groups. Group 1 (experimental): topical application of toluidine blue with micropipette was applied, and after 10 min, the patients were treated with a 630-nm GaAlAs laser (power density: 10 mW/cm(2)) during two visits. Group 2 (control) used mouthwash diluted with dexamethasone (tab 0/5 in 5 ml water) for 5 min, and then, it was spat out

2014 Lasers in medical science

188. Topical Corticosteroids Minimise the Risk of Postinflammatory Hyper-pigmentation After Ablative Fractional CO2 Laser Resurfacing in Asians. (PubMed)

Topical Corticosteroids Minimise the Risk of Postinflammatory Hyper-pigmentation After Ablative Fractional CO2 Laser Resurfacing in Asians. Postinflammatory hyperpigmentation (PIH) is the most common adverse effect of laser treatment in dark-skinned individuals. Little is known whether PIH can be prevented or minimised. The objective of this study was to investigate the effect of short-term application of topical corticosteroids on the incidence of PIH after ablative fractional resurfacing (...) weekly for the first month and at 2 and 3 months post-treatment. The side of the face treated with petrolatum alone had significantly (p < 0.001) higher incidence of PIH (75%) after laser irradiation than the side of the face treated with topical corticosteroids and petrolatum (40%). The PIH occurring on the petrolatum-treated sides had significantly higher intensity (p < 0.001) and was spread over a significantly larger area (p < 0.001), compared with the corticosteroid- and petrolatum-treated sides

Full Text available with Trip Pro

2014 Acta Dermato-Venereologica

189. A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment. (PubMed)

A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment. To date, no therapeutic option has been established for sudden deafness refractory to systemic corticosteroids. This study aimed to examine the efficacy and safety of topical insulin-like growth factor-1 (IGF-1) therapy in comparison to intratympanic corticosteroid therapy.We randomly assigned patients with sudden deafness refractory (...) to systemic corticosteroids to receive either gelatin hydrogels impregnated with IGF-1 in the middle ear (62 patients) or four intratympanic injections with dexamethasone (Dex; 58 patients). The primary outcome was the proportion of patients showing hearing improvement (10 decibels or greater in pure-tone average hearing thresholds) 8 weeks after treatment. The secondary outcomes included the change in pure-tone average hearing thresholds over time and the incidence of adverse events.In the IGF-1 group

Full Text available with Trip Pro

2014 BMC Medicine

190. Early Addition of Topical Corticosteroids in the Treatment of Bacterial Keratitis. (PubMed)

Early Addition of Topical Corticosteroids in the Treatment of Bacterial Keratitis. Scarring from bacterial keratitis remains a leading cause of visual loss.To determine whether topical corticosteroids are beneficial as an adjunctive therapy for bacterial keratitis if given early in the course of infection.The Steroids for Corneal Ulcers Trial (SCUT) was a randomized, double-masked, placebo-controlled trial that overall found no effect of adding topical corticosteroids to topical moxifloxacin (...) hydrochloride in bacterial keratitis. Here, we assess the timing of administration of corticosteroids in a subgroup analysis of the SCUT. We define earlier administration of corticosteroids (vs placebo) as addition after 2 to 3 days of topical antibiotics and later as addition after 4 or more days of topical antibiotics.We assess the effect of topical corticosteroids (vs placebo) on 3-month best spectacle-corrected visual acuity in patients who received corticosteroids or placebo earlier vs later. Further

Full Text available with Trip Pro

2014 JAMA ophthalmology

191. Topical corticosteroid reduces inflammation without compromising efficacy of photodynamic therapy for actinic keratoses a randomised clinical trial. (PubMed)

Topical corticosteroid reduces inflammation without compromising efficacy of photodynamic therapy for actinic keratoses a randomised clinical trial. Photodynamic therapy (PDT) is an effective and established treatment for actinic keratoses (AK) and nonmelanoma skin cancer. The main side-effects of PDT are post-treatment erythema and oedema, and pain during illumination. Severe erythema after PDT enhances the down time associated with the treatment.To evaluate in a randomized intraindividual (...) study whether use of a topical corticosteroid just before and just after PDT would reduce treatment-induced erythema compared with conventional PDT.Twenty-two patients with multiple AKs in the face and scalp were treated with methyl aminolaevulinate PDT in two symmetrical areas. One area was randomized to superpotent corticosteroid (clobetasol propionate) before and just after PDT. Objective and visual erythema, protoporphyrin IX (PpIX) fluorescence and pain were evaluated.Topical corticosteroid

2014 The British journal of dermatology

192. Efficacy of honey in comparison to topical corticosteroid for treatment of recurrent minor aphthous ulceration: A randomized, blind, controlled, parallel, double-center clinical trial. (PubMed)

Efficacy of honey in comparison to topical corticosteroid for treatment of recurrent minor aphthous ulceration: A randomized, blind, controlled, parallel, double-center clinical trial. Recurrent aphthous ulceration represents a very common mucosal disorder that general dentists may encounter on a daily basis, and for which there is no curative treatment. The best treatment that can be achieved is to avoid local traumatic precipitants, lessen the pain and duration of ulceration by suppressing (...) period.There were 94 subjects, with 180 minor recurrent aphthous ulcerations. The ulcers were distributed as 67, 57, and 56 ulcers for honey, topical corticosteroid, and Orabase treatment, respectively. There was a statistically significant difference between the honey group and the other two groups in terms of reduction of ulcer size, days of pain, and degree of erythema. No side effects were reported in any group.Honey was found to be effective and safe in reducing minor aphthous ulcer pain, size

2014 Quintessence international (Berlin, Germany : 1985)

193. Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids (PubMed)

Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids To report the case of an adult male with X-linked retinoschisis (XLRS) who presented with cystoid macular edema (CME) that responded consistently to treatment with intravitreal steroids.A 39 year old male with unilateral presentation of CME after repair of a retinal detachment secondary to XLRS responded initially to an injection of intravitreal triamcinolone acetonide (IVTA). Central subfield thickness on OCT (...) was reduced. Three months later, the CME recurred and he was unresponsive to topical treatment so repeat IVTA was given, and the CME once again was reduced dramatically. After the next recurrence, intravitreal dexamethasone implant treatment was initiated and successful at treating recurrences in 3 month intervals for 5 additional injections. Finally, an intravitreal fluocinolone acetonide implant was surgically placed with control of CME.Corticosteroids have never been reported to be effective in CME

Full Text available with Trip Pro

2016 American journal of ophthalmology case reports

194. Original article title: "Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial". (PubMed)

Original article title: "Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial". Vitiligo is the most prevalent pigmentary disorder which occurs worldwide, with an incidence rate between 0.1-4 percent. It is anticipated that the discovery of biological pathways of vitiligo pathogenesis will provide novel therapeutic and prophylactic targets for future approaches (...) to the treatment and prevention of vitiligo. The purposes of this study were evaluating the efficacy of supplemental zinc on the treatment of vitiligo.This randomized clinical trial was conducted for a period of one year. Thirty five patients among 86 participants were eligible to entrance to the study. The patients in two equal randomized groups took topical corticosteroid and combination of oral zinc sulfate-topical corticosteroid.The mean of responses in the corticosteroid group and the zinc sulfate

Full Text available with Trip Pro

2011 BMC dermatology

195. Socio-demographic factors do not have a large influence on psoriasis patients' adherence to topical treatment. (PubMed)

Socio-demographic factors do not have a large influence on psoriasis patients' adherence to topical treatment. Topical drugs containing corticosteroids are the most frequently used treatments for mild-to-moderate psoriasis, but adherence rates to topical drugs are low and up to 80% of psoriasis patients are classified as non-adherent, which present a barrier to treatment success.3 Barriers to treatment adherence can be divided into socio-demographic, healthcare, disease, treatment, and patient (...) -related factors. In a prospective study by Zaghloul et al., adherence to unspecified topical and systemic antipsoriatic drugs was investigated by counting pills or weighing medication bottles; lower adherence was associated with being single, male, or unemployed. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

196. Allergic contact dermatitis from topical ophthalmic medications: keep an eye on it! (PubMed)

Allergic contact dermatitis from topical ophthalmic medications: keep an eye on it! Allergic contact dermatitis (ACD) from topical ophthalmic medications is often overlooked.To study the demographic characteristics, lesion locations, and associated medical conditions of the patients with ACD from ophthalmic drugs, and to identify the most common allergenic culprits, as well as trends in frequencies over the years.From January 1990 until December 2016, 16 065 patients were investigated in our (...) clinic; all patients with a positive patch-test reaction to eye medication or its ingredient(s) having caused ACD were studied. For each allergen identified, the number of positive test results compared with the total number of those in the total population, as well as trends across three periods, namely 1990-1998, 1999-2007, and 2008-2016 were studied.118 patients (0.7%) presented with positive patch-test results to ingredients of, and/or topical ophthalmic medications. Aminoglycoside antibiotics

2019 Contact Dermatitis

197. Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial. (PubMed)

a reduction in CS, VAS, and CD133 expressions after treatment termination (p < 0.001). Pimecrolimus-treated lesions showed significant higher 1st week reduction in severity (33.1% (22.2)), pain score (57.53% (14.27)), less recurrence in follow-up period and less CD133 expression by the end of the 1st 4 weeks compared with betamethasone.Pimecrolimus showed earlier clinical response and less recurrence rate compared with standard topical corticosteroid in symptomatic OLP lesions, and both treatment reduced (...) Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial. Oral lichen plans (OLP) is a potentially malignant inflammatory mucocutaneous disease. CD133 is an investigated surface marker for cancer stem-like cells (CSCs) that may be involved in tumor initiation in head and neck carcinomas. We compared short-term clinical effectiveness of topical pimecrolimus as selective inflammatory cytokine release inhibitor with betamethasone cream for erosive/atrophic OLP

Full Text available with Trip Pro

2019 Clinical oral investigations

198. Topical Steroid Withdrawal: A Case Series of 10 Children. (PubMed)

Topical Steroid Withdrawal: A Case Series of 10 Children. Concerns about topical steroid withdrawal are causing some patients to cease long-term topical corticosteroid therapy, however, little is known about the ensuing clinical outcomes. This qualitative case series studied 10 children whose parents stopped their chronic topical corticosteroid use and subsequently developed features typically reported in adults experiencing topical steroid withdrawal. Patients were seen in an Australian (...) general practice between April 2014 and October 2018, with follow-up periods ranging from 18 months to 4 years. Symptoms were difficult initially for the children and their families, however, all ultimately improved. At the final review, 4 of the children had clear skin and another 4 had symptoms consistent with their original, pre-treatment atopic dermatitis. More research is required into long-term topical corticosteroid use and its discontinuation, including topical steroid withdrawal, particularly

Full Text available with Trip Pro

2019 Acta Dermato-Venereologica

199. Tinea Versicolor of the Neck As Side Effect of Topical Steroids For Alopecia Areata. (PubMed)

Tinea Versicolor of the Neck As Side Effect of Topical Steroids For Alopecia Areata. Treatment of alopecia areata (AA) involves use of high potency topical corticosteroids under occlusion that, even very effective, can lead to several adverse effects.We report 10 cases of patients with AA that, after using high potency topical corticosteroids, have developed tinea versicolor of the neck area.Ten patients with AA, aged 18-38 years, were prescribed with clobetasone propionate 0.05% cream under (...) but possible side effect of prolonged application of high potency topical steroids on the scalp. These cases reinforce the importance of careful dermatologic examination and recommend preventive measures in patients with alopecia areata that are using these drugs.

2019 Journal of Dermatological Treatment

200. Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis. (PubMed)

Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis. TCS (topical corticosteroids) is the first-line drug in the treatment of oral lichen planus (OLP). However, the value of topical calcineurin inhibitors (TCI) including tacrolimus, pimecrolimus and cyclosporine for OLP is still controversial.The article was carried out to compare the efficacy and safety of TCI with TCS for OLP.We searched PubMed/EMBASE/the Cochrane Central Register

2019 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>